CureVac (CVAC)
(Delayed Data from NSDQ)
$3.10 USD
+0.13 (4.38%)
Updated May 14, 2024 04:00 PM ET
After-Market: $3.10 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Income Statements
Fiscal Year end for CureVac NV falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 58 | 71 | 116 | 56 | NA |
Cost Of Goods | 135 | 194 | 267 | 16 | NA |
Gross Profit | -76 | -123 | -152 | 40 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 220 | 140 | 311 | 165 | 0 |
Income After Depreciation & Amortization | -297 | -263 | -463 | -125 | 0 |
Non-Operating Income | 18 | 4 | 11 | 2 | NA |
Interest Expense | 3 | 4 | 12 | 25 | NA |
Pretax Income | -281 | -263 | -463 | -148 | NA |
Income Taxes | 0 | 0 | -1 | -1 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -282 | -262 | -462 | -148 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -282 | -262 | -462 | -148 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -271 | -238 | -445 | -113 | 0 |
Depreciation & Amortization (Cash Flow) | 25 | 25 | 18 | 12 | NA |
Income After Depreciation & Amortization | -297 | -263 | -463 | -125 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | NA | 188.66 | 186.30 | 132.20 | NA |
Diluted EPS Before Non-Recurring Items | NA | -1.42 | -2.48 | -1.12 | NA |
Diluted Net EPS (GAAP) | -1.28 | -1.39 | -2.48 | -1.12 | NA |
Fiscal Year end for CureVac NV falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 24.33 | 17.94 | 8.26 | 7.65 |
Cost Of Goods | NA | 57.83 | 26.43 | 28.19 | 22.15 |
Gross Profit | NA | -33.51 | -8.49 | -19.93 | -14.50 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 61.38 | 50.32 | 58.37 | 50.29 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -94.89 | -58.81 | -78.30 | -64.79 |
Non-Operating Income | NA | -3.10 | 10.28 | 6.76 | 4.17 |
Interest Expense | NA | -4.71 | 4.45 | 1.94 | 1.02 |
Pretax Income | NA | -93.28 | -52.98 | -73.48 | -61.63 |
Income Taxes | NA | 0.18 | 0.01 | 0.03 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -93.45 | -52.98 | -73.51 | -61.63 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -93.45 | -52.98 | -73.51 | -61.63 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | 221.28 | 223.88 | 212.66 |
Diluted EPS Before Non-Recurring Items | NA | NA | -0.24 | -0.33 | -0.29 |
Diluted Net EPS (GAAP) | NA | -0.42 | -0.24 | -0.33 | -0.29 |